…
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Intellia Therapeutics is a clinical-stage company developing CRISPR/Cas9 genome-editing therapies using in vivo and ex vivo delivery to treat genetic diseases. Long-term growth drivers include clinical progress of liver-directed and other programs, expansion of delivery technologies such as lipid nanoparticles, and pipeline growth into additional inherited and hepatic disorders that may benefit from one-time durable edits.
Key risks are clinical and regulatory uncertainty around safety and durability of edits, intense competition in gene editing, and ongoing cash needs that could require dilutive financing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -412.69M | -519.02M | -481.19M | -474.19M | -267.89M |
| Net income | -412.69M | -519.02M | -481.19M | -490.21M | -259.72M |
| Selling general administrative | 119.80M | 125.83M | 116.50M | 90.31M | 71.10M |
| Gross profit | 51.75M | 47.59M | 27.30M | 52.12M | 33.05M |
| Reconciled depreciation | 15.92M | 10.29M | 8.98M | 7.57M | 6.89M |
| Ebit | -412.69M | -519.02M | -481.19M | -458.16M | -274.74M |
| Ebitda | -396.77M | -508.74M | -472.22M | -444.68M | -267.85M |
| Depreciation and amortization | 15.92M | 10.29M | 8.98M | 13.48M | 6.89M |
| Non operating income net other | - | - | - | -17.66M | 0.04M |
| Operating income | -440.99M | -534.26M | -515.29M | -458.16M | -267.85M |
| Other operating expenses | 508.66M | 592.14M | 551.57M | 510.29M | 300.90M |
| Interest expense | - | - | - | 8.54M | 6.89M |
| Interest income | 29.20M | 47.81M | 49.83M | 8.54M | 1.28M |
| Net interest income | 29.20M | 47.81M | 49.83M | 8.54M | 1.28M |
| Income tax expense | - | - | -49.73M | 16.02M | -8.17M |
| Total revenue | 67.67M | 57.88M | 36.27M | 52.12M | 33.05M |
| Total operating expenses | 492.74M | 581.86M | 542.59M | 510.29M | 300.90M |
| Cost of revenue | 15.92M | 10.29M | 8.98M | - | - |
| Total other income expense net | 28.30M | 15.24M | 34.10M | -16.02M | -0.04M |
| Net income from continuing ops | -412.69M | -519.02M | -481.19M | -474.19M | -267.81M |
| Net income applicable to common shares | - | - | - | -474.19M | -267.89M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 842.13M | 1191.02M | 1300.98M | 1520.11M | 1294.46M |
| Other current assets | 68.36M | 29.83M | 49.65M | 20.41M | 18.58M |
| Total liab | 170.73M | 319.06M | 250.81M | 284.53M | 254.22M |
| Total stockholder equity | 671.39M | 871.96M | 1050.17M | 1235.58M | 1040.24M |
| Other current liab | 49.86M | 55.35M | 67.02M | 60.88M | 43.31M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -2590.09M | -2177.40M | -1658.38M | -1177.19M | -703.00M |
| Other liab | - | - | - | 43.96M | 63.48M |
| Other assets | - | - | - | 15.73M | 4.76M |
| Cash | 155.46M | 189.18M | 226.75M | 523.51M | 123.41M |
| Total current liabilities | 103.88M | 110.85M | 115.21M | 126.55M | 125.83M |
| Current deferred revenue | 7.29M | 20.66M | 22.14M | 43.84M | 63.76M |
| Net debt | -62.13M | 21.02M | -111.40M | -392.80M | -49.38M |
| Short term debt | 26.48M | 20.25M | 18.60M | 16.68M | 9.11M |
| Short long term debt total | 93.33M | 210.20M | 115.35M | 130.70M | 74.02M |
| Other stockholder equity | 3260.44M | 3048.74M | 2710.80M | 2420.22M | 1745.87M |
| Property plant equipment | - | - | - | 27.92M | 20.97M |
| Total current assets | 527.71M | 639.86M | 998.33M | 1216.80M | 769.30M |
| Long term investments | 190.79M | 304.48M | 154.51M | 142.32M | 425.05M |
| Net tangible assets | - | - | - | 1369.53M | 1168.63M |
| Short term investments | 294.42M | 412.33M | 685.48M | 669.12M | 625.28M |
| Net receivables | 9.47M | 8.52M | 36.46M | 3.77M | 2.03M |
| Inventory | - | - | - | -69.34M | -337.36M |
| Accounts payable | 20.25M | 14.59M | 7.45M | 5.15M | 9.65M |
| Accumulated other comprehensive income | 1.03M | 0.60M | -2.26M | -7.46M | -2.63M |
| Common stock total equity | - | - | - | 0.01M | 0.01M |
| Retained earnings total equity | - | - | - | -1177.19M | -703.00M |
| Non currrent assets other | 155.25M | 260.21M | - | 72.98M | 87.69M |
| Non current assets total | 314.42M | 551.15M | 302.65M | 303.32M | 525.16M |
| Capital lease obligations | 93.33M | 210.20M | 115.35M | 130.70M | 74.02M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 229.16M | 125.57M | -107.44M | 160.31M | -535.02M |
| Change to liabilities | - | - | - | 11.34M | 17.79M |
| Total cashflows from investing activities | 125.57M | 125.57M | -31.35M | 160.31M | -550.78M |
| Total cash from financing activities | 185.75M | 185.75M | 130.32M | 582.96M | 736.69M |
| Change to operating activities | - | - | - | 15.91M | 7.82M |
| Net income | -519.02M | -519.02M | -481.19M | -474.19M | -267.89M |
| Change in cash | -37.57M | -37.57M | -295.11M | 409.98M | -39.12M |
| Begin period cash flow | 240.35M | 240.35M | 535.46M | 125.49M | 164.61M |
| End period cash flow | 202.79M | 202.79M | 240.35M | 535.46M | 125.49M |
| Total cash from operating activities | -348.88M | -348.88M | -394.09M | -333.29M | -225.03M |
| Issuance of capital stock | 128.18M | 176.90M | 519.83M | 565.79M | 693.57M |
| Depreciation | 10.29M | 10.29M | 8.98M | 7.57M | 6.89M |
| Other cashflows from investing activities | 20.97M | 0.00M | - | -44.68M | -3.00M |
| Change to inventory | - | - | -19.51M | - | 7.82M |
| Change to account receivables | -0.95M | 27.94M | -32.69M | -1.74M | 0.10M |
| Sale purchase of stock | - | - | - | 582.96M | 1861.02M |
| Other cashflows from financing activities | 54.26M | 8.85M | 10.53M | 17.17M | 43.12M |
| Change to netincome | - | - | - | 171.79M | 45.68M |
| Capital expenditures | 5.78M | 5.78M | 13.98M | 58.39M | 12.76M |
| Change receivables | - | - | - | -1.74M | 0.10M |
| Cash flows other operating | - | - | - | -52.07M | -43.73M |
| Cash and cash equivalents changes | - | - | - | 409.98M | -39.12M |
| Change in working capital | -73.75M | 11.88M | -52.45M | -53.87M | -22.90M |
| Stock based compensation | 154.27M | 154.27M | 134.05M | 91.40M | 47.01M |
| Other non cash items | 79.33M | -6.29M | -3.47M | 95.80M | 2.94M |
| Free cash flow | -354.66M | -354.66M | -408.07M | -391.68M | -237.79M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics Inc |
-0.01 0.10% |
9.85 | - | - | 26.75 | 2.29 | 21.83 | -5.51 |
| NVO Novo Nordisk A/S |
-0.80 1.91% |
40.80 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.08 0.39% |
535.71 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
9.09 0.95% |
961.49 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats ("CRISPR")/CRISPR associated 9 ("Cas9") technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. John M. Leonard M.D. | Pres, CEO & Director | 1957 |
| Mr. Glenn G. Goddard CPA | Exec. VP, CFO & Treasurer | 1971 |
| Dr. Laura Sepp-Lorenzino Ph.D. | Exec. VP & Chief Scientific Officer | 1961 |
| Mr. James E. Basta Esq., J.D. | Exec. VP, Gen. Counsel & Corp. Sec. | 1966 |
| Dr. David Lebwohl M.D. | Exec. VP & Chief Medical Officer | 1955 |
| Mr. Nessan Bermingham Ph.D. | Founder & Member of Scientific Advisor Board | 1973 |
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder | 1986 |
| Dr. Andrew May | Founder and Member of Scientific Advisor Board | NA |
| Dr. Jennifer A. Doudna Ph.D. | Founder & Member of Scientific Advisor Board | 1964 |
| Dr. Derrick J. Rossi Ph.D. | Founder & Member of Scientific Advisor Board | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.